Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
|
|
- Sheena Holt
- 5 years ago
- Views:
Transcription
1 ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi Wang, 1 Jiguang Fei, 1 Suxiong Deng, 1 Jun Li, 1 Gang Huang, 1 Qian Fu, 1 Lizhong Chen 1 Abstract Objectives: To compare the efficacy and safety of thymoglobulin compared with basiliximab in patients who had kidney transplants and are at high risk for acute rejection and delayed graft function. Materials and Methods: A retrospective review of patients who had 1 or more risk factors for acute rejection and delayed graft function and who were given either thymoglobulin or basiliximab for induction therapy. Incidences of acute rejection, antibody-treated acute rejection, delayed graft function, chronic rejection, cancer, infection, leucopenia, and thrombocytopenia were compared between thymoglobulin and basiliximab groups. Serum creatinine levels within 1 year and long-term graft and patient survival also were compared. Results: A total of 327 patients were included. Incidences of acute rejection, antibody-treated acute rejection, delayed graft function, and chronic rejection were significantly lower in the thymoglobulin group than in the basiliximab group (P <.05). Serum creatinine levels were lower in the thymoglobulin group on postoperative days 7, 14, and 30 (P <.05). There were no statistically significant differences regarding long-term graft and patient survival, cancer, or total infection rate between the groups. Incidences of Cytomegalovirus infection, leucopenia, and thrombocytopenia were significantly higher in the thymoglobulin group (P <.05). From the 1 Organ Transplant Center and the 2 Department of Hematology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China Acknowledgements: The authors have no conflicts of interest to disclose. This study was supported by 5010 clinical research funding from Sun Yat-Sen University. Corresponding author: Lizhong Chen, MD, Organ Transplant Center, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Rd II, Guangzhou, Guangdong, China, Phone: Fax: clz1@medmail.com.cn Experimental and Clinical Transplantation (2013) 4: Conclusions: Thymoglobulin may improve shortterm outcomes, compared with basiliximab, in patients who had kidney transplants and are at high risk for acute rejection and delayed graft function. However, long-term outcomes are similar with thymoglobulin and basiliximab. Key words: Thymoglobulin, Basiliximab, Kidney transplant Introduction In patients with kidney transplants, acute rejection has been shown to significantly reduce long-term graft survival. 1 Delayed graft function (DGF) may increase the incidence of acute rejection and have negative effects on long-term graft and patient survival. 2,3 Some risk factors have been reported to be related to acute rejection and DGF after kidney transplant, such as higher donor age, long cold ischemia time, repeat transplant, positive panel-reactive antibody test results, and mismatched histocompatibility leukocyte antigen (HLA). 4-6 Induction therapy has been widely used to reduce acute rejection and DGF after kidney transplants. Thymoglobulin and basiliximab are the most commonly prescribed medications in induction therapy. Several studies have shown that both thymoglobulin and basiliximab could significantly decrease the incidence of acute rejection and DGF after a kidney transplant. 7-9 However, whether these drugs have similar efficacy and safety in patients who are at high risk for acute rejection and DGF remains to be determined. In the present study, we retrospectively reviewed 327 patients who had kidney transplants and 1 or more risk factors for acute rejection and DGF and who were given either thymoglobulin or basiliximab for Copyright Başkent University 2013 Printed in Turkey. All Rights Reserved. DOI: /ect
2 Guodong Chen et al /Experimental and Clinical Transplantation (2013) 4: induction therapy. Drug efficacy and safety were compared between these 2 induction therapy groups. Materials and Methods The present study was a retrospective cohort study conducted at The First Affiliated Hospital of Sun Yat-Sen University in South China. The study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Sun Yat-Sen University. No prisoner organs were used in this study. All protocols conformed with the ethical guidelines of the 1975 Helsinki Declaration. Inclusion criteria for patients included the following: (1) received deceased-donor kidney transplant at The First Affiliated Hospital of Sun Yat-Sen University between January 1998 and December 2005, (2) aged 18 to 65 years, (3) at least 1 risk factor for acute rejection and DGF as described in Table 1, and (4) received either thymoglobulin or basiliximab as induction therapy. The exclusion criteria included the following: (1) received multiple organ transplants, (2) received immunosuppressive therapy before kidney transplant, (3) received sirolimus or azathioprine as maintenance therapy, (4) seropositive for hepatitis B surface antigen or antibody against hepatitis C virus, and (5) cancer within 2 years before kidney transplant. table 1. Comparison of Risk Factors for Acute Rejection and Delayed Graft Function Between Thymoglobulin and Basiliximab Groups (N=327) Group* Risk Factor (n=149) (n=178) P Value Donor age > 50 y 10 (6.7%) 13 (7.3%).835 Cold ischemia time > 24 h 58 (38.9%) 72 (40.4%).779 Repeat transplant 67 (44.9%) 75 (42.1%).607 PRA > 10% 49 (32.9%) 59 (33.1%).906 HLA mismatched > 4 loci 13 (8.7%) 15 (8.4%).924 Risk factors, No. ± SD 2.3 ± ± Abbreviations: HLA, human leukocyte antigen; PRA, panel reactive antibody *Data presented as No. (%) unless otherwise indicated. Induction therapy Patients included in the study were divided into a thymoglobulin group or basiliximab group depending on whether they received thymoglobulin or basiliximab as induction therapy. Patients in the thymoglobulin group received thymoglobulin (1 mg/kg/d intravenously [IV]) during kidney transplant surgery and on days 1 and 2 after surgery. Patients in the basiliximab group received basiliximab (20 mg IV) during kidney transplant surgery and on day 4 after surgery. Methylprednisolone (500 mg/d IV) was administered in both groups during transplant surgery and on postoperative days 1 and 2. Maintenance immunosuppressive regimen Patients received mycophenolate mofetil (MMF) 750 mg orally twice daily immediately after kidney transplant, and MMF was tapered to 500 mg twice daily within 1 month and to 250 mg twice daily after 1 year. Tacrolimus and cyclosporine were started on postoperative day 3. The initial dosage of tacrolimus was 0.1 mg/kg daily. The tacrolimus trough level was 5 to 10 ng/ml within the first 6 months and then tapered to 4 to 6 ng/ml within 1 year, and 3 to 5 ng/ml after 1 year. The initial dose of cyclosporine was 5 mg/kg daily. Its trough level was 150 to 250 ng/ml within the first 6 months, then tapered to 130 to 180 ng/ml within 1 year and 120 to 150 ng/ml after 1 year. Prednisone 30 mg daily was stated on postoperative day 3 and tapered to 5 mg daily within 6 months. Diagnosis and treatment Acute rejection was diagnosed with such clinical manifestations as fever, oliguria, and serum creatinine elevation, and the diagnosis was confirmed by allograft biopsy. When acute rejection was diagnosed, methylprednisolone (500 mg/d IV) was administered for 3 days. If steroid therapy had no beneficial effect, anti-thymocyte globulin (rabbit) (1 mg/kg/d) or muromonab-cd3 (5 mg/d) was administered for 7 to 10 days. Prophylaxis All transplant recipients received intravenous ganciclovir sodium for cytomegalovirus (CMV) prophylaxis from postoperative day 1 to day 14. This administration was followed by maintenance therapy with oral ganciclovir for 90 days. Sulfamethoxazole was given orally for 3 months for Pneumocystis carinii prophylaxis. Primary endpoints The primary efficacy endpoints included acute rejection, antibody-treated acute rejection, DGF, chronic rejection, graft loss, and patient death. Longterm graft and patient survival, serum creatinine
3 312 Guodong Chen et al /Experimental and Clinical Transplantation (2013) 4: Exp Clin Transplant level within 1 year, infection, cancer, leucopenia, and thrombocytopenia also were analyzed. Definition Acute rejection and chronic rejection were confirmed by biopsy. Antibody-treated acute rejection was defined as acute rejection in which anti-thymocyte globulin or muromonab-cd3 steroids, were required for treatment. Delayed graft function was defined as a requirement for dialysis during the first week after kidney transplant. Statistical analyses All data were analyzed by SPSS statistical software (SPSS: An IBM Company, Windows version 16.0, IBM Corporation, Armonk, New York, USA). Graft and patient survival were calculated by the Kaplan-Meier method, and survival curves were compared using the log-rank test. Categorical variables were compared using the chi-square test or Fisher exact test. Continuous variables were compared using the t test. A value for P <.05 was considered significant. Results A total of 327 patients were included in the present study. Among these patients, 149 (45.6%) received thymoglobulin and 178 (54.4%) received basiliximab. The median follow-up was 8.2 years in the thymoglobulin group and 8.5 years in the basiliximab group. Risk factors for acute rejection and DGF in the thymoglobulin and basiliximab groups are compared in Table 1. Baseline demographic characteristics for patients in the thymoglobulin and basiliximab groups are summarized in Table 2. The data show that there were no significant differences in risk factors, sex, age, weight, dialysis, or maintenance therapy between the thymoglobulin and basiliximab groups. The acute rejection rate in the thymoglobulin group was 16.8%, compared with 30.3% in the basiliximab group (P =.004). Antibody-treated acute rejection rate was 5.4% versus 12.4% in the thymoglobulin group versus the basiliximab group (P =.029). These results show that thymoglobulin was significantly more effective than basiliximab in reducing acute rejection, especially antibody-treated acute rejection, after kidney transplant. Banff criteria suggest that biopsy-proven acute rejection was more severe in the basiliximab group than in the thymoglobulin group (Table 3), though chisquare test results indicated no statistically significant difference (P =.268). Incidences of DGF and chronic rejection were significantly lower in the thymoglobulin group than in the basiliximab group (26.2% vs 37.1%, 10.7% vs 19.1%; P <.05), as shown in Table 4. table 2. Baseline Demographic Characteristics of Thymoglobulin and Basiliximab Groups (N=327) Groups (N=327)* Characteristic (n=149) (n=178) P Value Sex Male 91 (61.1%) 122 (68.5%).158 Female 58 (38.9%) 56 (31.5%) Age, mean ± SD, y 43.9 ± ± Weight, mean ± SD, kg 57.2 ± ± Dialysis None 23 (15.4%) 25 (14.0%).769 Hemodialysis 78 (52.3%) 89 (50.0%) Peritoneal dialysis 48 (32.2%) 64 (36.0%) Maintenance therapy Tacrolimus + MMF + steroids 105 (70.5%) 128 (71.9%).774 Cyclosporine + MMF + steroids 44 (29.5%) 50 (28.1%) Abbreviations: MMF, mycophenolate mofetil *Data presented as No. (%) unless otherwise indicated. table 3. Comparison of Banff Classification in Biopsy-Proven Acute Rejection Between Thymoglobulin and Basiliximab Groups (N=79) Banff P Value Classification (n=25) (n=54) Type I A 10 (40.0%) 13 (24.1%).268 Type I B 7 (28.0%) 19 (35.2%) Type II A 4 (16.0%) 4 (7.4%) Type II B 3 (12.0%) 10 (18.5%) Type III 1 (4.0%) 8 (14.8%) Using R C (chi-square test) table 4. Comparison of Efficacy Endpoints Between Thymoglobulin and Basiliximab Groups (N=327) Endpoint (n=149) (n=178) P Value Delayed graft function 39 (26.2) 66 (37.1).035 Acute rejection 25 (16.8) 54 (30.3).004 Antibody-treated acute rejection 8 (5.4) 22 (12.4).029 Chronic rejection 16 (10.7) 34 (19.1).036 Graft loss 62 (41.6) 79 (44.4).614 Patient death 31 (20.8) 39 (21.9).808
4 Guodong Chen et al /Experimental and Clinical Transplantation (2013) 4: No statistically significant differences were found in long-term graft survival (Figure 1) or patient survival (Figure 2) between the thymoglobulin and basiliximab groups. The causes of graft loss were similar in both groups, including death with functioning grafts, chronic rejection, acute rejection, and recurrent nephropathy. The causes of patient death also were similar in both groups, with infection, cardiovascular disease, and renal function failure being the most common causes. common in the thymoglobulin group than in the basiliximab group (28.2% vs 15.7%; P <.05). The incidence of cancer was similar in both groups. The leucopenia and thrombocytopenia rates were significantly higher in the thymoglobulin group than in the basiliximab group (22.8% vs 11.8%, 8.1% vs 2.8%; P <.05) (Table 5). Figure 3. Comparison of Serum Creatinine Levels within 1 Year After Kidney Transplant Between Thymoglobulin and Basiliximab Groups. *P <.05 Figure 1. Comparison of Long-Term Graft Survival After Kidney Transplant Between Thymoglobulin and Basiliximab Groups Using the Kaplan-Meier Method and Log-Rank Test Cum Survival Figure 2. Comparison of Long-Term Patient Survival After Kidney Transplant Between Thymoglobulin and Basiliximab Groups Using the Kaplan-Meier Method and Log-Rank Test Cum Survival Days After Transplant table 5. Comparison of Complications After Transplant Between Thymoglobulin and Basiliximab Groups (N=327) Complication (n=149) (n=178) P Value Infections 96 (64.4) 111 (62.4).699 CMV 42 (28.2) 28 (15.7).006 Non-CMV 25 (16.8) 24 (13.5).406 Bacteria 67 (45.0) 73 (41.0).472 Fungi 17 (11.4) 20 (11.2).975 Protozoa 3 (2.0) 2 (1.1).663 Cancer 3 (2.0) 4 (2.2).597 Leucopenia 34 (22.8) 21 (11.8).008 Thrombocytopenia 12 (8.1) 5 (2.8).033 Abbreviations: CMV, Cytomegalovirus Discussion Days After Transplant Serum creatinine levels were significantly lower in the thymoglobulin group than in the basiliximab group on postoperative days 7, 14, and 30 (P =.023,.015, and.032) (Figure 3). There was no statistically significant difference in total infection rate between the thymoglobulin and basiliximab groups (64.4% vs 64.2%; P >.05), but CMV infection was more In the present retrospective cohort study, we found that thymoglobulin could reduce the incidence of DGF and acute rejection in patients with kidney transplants and who were at high risk for acute rejection and DGF compared with basiliximab. Based on Banff criteria for biopsy-proven acute rejection, the severity of acute rejection was lower in the thymoglobulin group than in the basiliximab group. Thus, it was logical that antibody-treated acute rejection also was significantly decreased in
5 314 Guodong Chen et al /Experimental and Clinical Transplantation (2013) 4: Exp Clin Transplant thymoglobulin group compared to the basiliximab group. These results demonstrate that thymoglobulin was more effective than basiliximab in controlling the immune response and inflammatory damage to grafts in these high-risk recipients. One prospective study also reported that thymoglobulin could significantly decrease the incidences of acute rejection and antibody-treated rejection compared with basiliximab, but that study found no difference in the incidence of DGF between the 2 drugs. 10 Our results also suggest that thymoglobulin could improve short-term renal function. Within the first month after kidney transplant, the serum creatinine level was much improved in the thymoglobulin group compared to the basiliximab group perhaps because thymoglobulin reduced the DGF and acute rejection rates in these high-risk transplant recipients. Furthermore, our results show that thymoglobulin could reduce the incidence of chronic rejection. Because many studies have shown that DGF, acute rejection, and chronic rejection are major risk factors for graft loss, thymoglobulin has the potential to improve long-term outcomes in kidney transplant recipients. However, our data show no differences in long-term graft and patient survival between the thymoglobulin and basiliximab groups. Additional prospective studies are needed to compare the long-term efficacy between thymoglobulin and basiliximab. There was no statistically significant difference in total infection rate between the thymoglobulin and basiliximab groups, but the CMV infection rate was higher in thymoglobulin group. Although routine CMV prophylaxis was used for all recipients after kidney transplant, CMV infection remained common among these recipients. This high infection rate may have been the result of the high dosages of immunosuppressive drugs used in these recipients to counter their risks for DGF and acute rejection. Another factor to consider is that thymoglobulin depleted the T cells, but basiliximab only suppressed the T cells. Thus, it is reasonable that CMV infection would be higher in the thymoglobulin group. Because the incidences of leucopenia and thrombocytopenia also were higher in the thymoglobulin group, it is advisable to pay attention to the white blood cell and platelet counts postoperatively, and to reduce the dose of thymoglobulin if the white blood cell count is lower than /L so as to decrease the infection rate. Because this is a retrospective cohort study, the patients were not randomized into thymoglobulin and basiliximab groups. We recognize that some selection bias may exist in this study. Additional prospective and randomized studies are warranted to further compare the efficacy of thymoglobulin and basiliximab in high-risk patients receiving kidney transplants. In conclusion, our study shows that thymoglobulin could significantly reduce the incidences of acute rejection, DGF, and chronic rejection, as well as decrease the severity of acute rejection, in kidney transplant recipients who are at high risk for acute rejection and DGF, compared with basiliximab. Short-term renal function was better in the thymoglobulin group than in the basiliximab group, but long-term outcomes were similar between the groups. References 1. de Fijter JW. Rejection and function and chronic allograft dysfunction. Kidney Int Suppl. 2010;119:S38-S Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3): Narayanan R, Cardella CJ, Cattran DC, et al. Delayed graft function and the risk of death with graft function in living donor kidney transplant recipients. Am J Kidney Dis. 2010;56(5): Doshi MD, Garg N, Reese PP, Parikh CR. Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation. 2011;91(6): Moreira P, Sá H, Figueiredo A, Mota A. Delayed renal graft function: risk factors and impact on the outcome of transplantation. Transplant Proc. 2011;43(1): Paramesh AS, Zhang R, Baber J, et al. The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transplant. 2010;24(6):E247-E Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation. 2010;90(12): Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006;26(12): McKeage K, McCormack PL. Basiliximab: a review of its use as induction therapy in renal transplantation. Bio Drugs. 2010;24(1): Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19): Shrestha BM, Haylor JL. Factors influencing long-term outcomes following renal transplantation: a review. JNMA J Nepal Med Assoc. 2007;46(167): Yarlagadda SG, Klein CL, Jani A. Long-term renal outcomes after delayed graft function. Adv Chronic Kidney Dis. 2008;15(3): Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donorspecific antibodies are due to acute rejection episodes. Transplantation. 2011;91(10):
Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationEvaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients
Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients Catherine A. Pennington, 1 Sarah M. Tischer, 1 Eliza Lee, 2 Sun Lee, 2 James Sindelar,
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationOutpatient Management of Delayed Graft Function Is Associated With Reduced Length of Stay Without an Increase in Adverse Events
American Journal of Transplantation 2016; 16: 1604 1611 Wiley Periodicals Inc. Brief Communication Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationHLA-Matched Kidney Transplantation in the Era of Modern Immunosuppressive Therapy
HLA-Matched Kidney Transplantation in the Era of Modern Immunosuppressive Therapy Arun Amatya, MD; Sandy Florman, MD; Anil Paramesh, MD; Anup Amatya, PhD Jennifer McGee, MD; Mary Killackey, MD; Quing Ren,
More informationSingle-dose thymoglobulin induction in living-donor renal transplantation
Ann Transplant, 2; (2): 5-58 Original Paper Received: 2.2.5 Accepted: 2.3.4 Published: 2..3 Authors Contribution: A Study Design B Data Collection C Statistical Analysis D Data Interpretation E Manuscript
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationAlemtuzumab Induction in Renal Transplantation
original article Induction in Renal Transplantation Michael J. Hanaway, M.D., E. Steve Woodle, M.D., Shamkant Mulgaonkar, M.D., V. Ram Peddi, M.D., Dixon B. Kaufman, M.D., Ph.D., M. Roy First, M.D., Richard
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationThe recovery status from delayed graft function can predict long-term outcome after deceased donor kidney transplantation
www.nature.com/scientificreports Received: 5 June 2017 Accepted: 6 October 2017 Published: xx xx xxxx OPEN The recovery status from delayed graft function can predict long-term outcome after deceased donor
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationThe New England Journal of Medicine PROSPECTIVE STUDY OF POLYOMAVIRUS TYPE BK REPLICATION AND NEPHROPATHY IN RENAL-TRANSPLANT RECIPIENTS
PROSPECTIVE STUDY OF POLYOMAVUS TYPE BK REPLICATION AND NEPHROPATHY IN RENAL-TRANSPLANT RECIPIENTS HANS H. HSCH, M.D., WENDY KNOWLES, PH.D., MICHAEL DICKENMANN, M.D., JAKOB PASSWEG, M.D., THOMAS KLIMKAIT,
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationProton pump inhibitors do not increase the risk of acute rejection
ORIGINAL ARTICLE Proton pump inhibitors do not increase the risk of acute rejection G.A.J. van Boekel*, C.H.H. Kerkhofs, F. van de Logt, L.B. Hilbrands Department of Nephrology, Radboud University Medical
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 28 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationAlemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients
LIVER TRANSPLANTATION 17:32-37, 2011 ORIGINAL ARTICLE Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients Josh Levitsky, 1,2 Kavitha Thudi, 1 Michael G. Ison, 1,3 Edward Wang,
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationDown the Rabbit Hole: Optimized Dosing for Rabbit Anti-Thymocyte Globulin Induction in High Risk Renal Transplant Recipients
Down the Rabbit Hole: Optimized Dosing for Rabbit Anti-Thymocyte Globulin Induction in High Risk Renal Transplant Recipients Elisabeth Kincaide, PharmD PGY2 Solid Organ Transplant Pharmacy Resident University
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationReceived: 14 July 2016, Revised and Accepted: 23 July 2016
Vol 9, Issue 6, 2016 Online - 2455-3891 Print - 0974-2441 Research Article COMPARISON OF INDUCTION THERAPY USING ANTI-THYMOCYTE GLOBULIN AND USING BASILIXIMAB FOR LIVE DONOR KIDNEY TRANSPLANT RECIPIENTS:
More informationInduction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:1210-1214, 2006 ORIGINAL ARTICLE Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation Ashesh Shah, 1 Avinash Agarwal, 1 Richard Mangus,
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 27 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationBelatacept: An Update of Ongoing Clinical Trials
Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationRabbit Antithymocyte Globulin (Thymoglobulin Ò )
REVIEW ARTICLE Drugs 2010; 70 (6): 691-732 0012-6667/10/0006-0691/$55.55/0 ª 2010 Adis Data Information BV. All rights reserved. Rabbit Antithymocyte Globulin (Thymoglobulin Ò ) 25 Years and New Frontiers
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2006 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationClinical Study Over Ten-Year Kidney Graft Survival Determinants
International Nephrology Volume 2012, Article ID 302974, 5 pages doi:10.1155/2012/302974 Clinical Study Over Ten-Year Kidney Graft Survival Determinants Anabela Malho Guedes, 1, 2 Jorge Malheiro, 1 Isabel
More informationHeart Transplant: State of the Art. Dr Nick Banner
Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationNorth American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationPrimary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis
American Journal of Transplantation 2010; 10: 2026 2032 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationIntravenous immunoglobulin in BK virus nephropathy
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Intravenous immunoglobulin in BK virus nephropathy Elizabeth I. Anyaegbu Driscoll Children's Hospital Stanley
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationRyszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation
Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationLate-Onset Cytomegalovirus (CMV) in Lung Transplant Recipients: Can CMV Serostatus Guide the Duration of Prophylaxis?
American Journal of Transplantation 2013; 13: 376 382 Wiley Periodicals Inc. C Copyright 2012 American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04339.x
More informationMycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience
840 O.A. Raheem et al. Nephrol Dial Transplant (2012) 27: 840 844 doi: 10.1093/ndt/gfr263 Advance Access publication 28 May 2011 Mycophenolate mofetil in low-risk renal transplantation in patients receiving
More informationThe addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY
nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin
More informationJamalbek Ashimov, Janybek Gaibyldaev SRI of Heart Surgery and Organ Transplantation, Bishkek, Kyrgyzstan
Brief Report Types and structure of complications, and causes of mortality with different combinations of immunosuppressants in patients of undergoing organ transplantation Jamalbek Ashimov, Janybek Gaibyldaev
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationABO-incompatible kidney transplantation in elderly patients over 60 years of age
Int Urol Nephrol (2012) 44:1563 1570 DOI 10.1007/s11255-012-0231-z NEPHROLOGY - ORIGINAL PAPER ABO-incompatible kidney transplantation in elderly patients over 60 years of age Junji Uchida Tomoaki Iwai
More informationTrends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection
2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant
More informationABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR
ABO ABO ABO ABO ABO ABO ABO ABO ABO ABO.. ABO ABO. ABO. ABO ABO Key words ABO ABO A B antibody-mediated rejection, AMR Alexandre ABO double filtration plasmapheresis, DFPP ABO ABO n ABO n p-value R.....
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationThymoglobulin induction dosing strategies in a low-risk kidney transplant population: Three or four days?
Washington University School of Medicine Digital Commons@Becker Open Access Publications 1-1-21 Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: Three or four days?
More informationRe: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)
January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationOrgan rejection is one of the serious
Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.
More informationImpact of Cytomegalovirus Disease in D+/R Kidney Transplant Patients Receiving 6 Months Low-Dose Valganciclovir Prophylaxis
American Journal of Transplantation 2011; 11: 1936 1942 Wiley Periodicals Inc. C 2011 The Authors Journal compilation C 2011 The American Society of Transplantation and the American Society of Transplant
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationProspective, Randomized, Multi-Center Trial of Antibody Induction Therapy in Simultaneous Pancreas-Kidney Transplantation
American Journal of Transplantation 2003; 3: 855 864 Copyright # Blackwell Munksgaard 2003 Blackwell Munksgaard ISSN 1600-6135 Prospective, Randomized, Multi-Center Trial of Antibody Therapy in Simultaneous
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationThe privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white
More informationPost Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ
Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ Art of Good Cooking Good Ingredient Good donor + OK recipient Good technique Good team Good timing Good
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multi-center, Randomized, Open-label, Pilot and Exploratory Study Investigating Safety and Efficacy in OPTIMIZEd Dosing of Advagraf Kidney
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationRisk factors in the progression of BK virus-associated nephropathy in renal transplant recipients
ORIGINAL ARTICLE Korean J Intern Med 15;3:865-872 http://dx.doi.org/1.394/kjim.15.3.6.865 Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients Hae Min Lee 1,*,
More informationHigher tacrolimus trough levels on days 2 5 post-renal transplant are associated with reduced rates of acute rejection
Clin Transplant 2009: 23: 462 468 DOI: 10.1111/j.1399-0012.2009.01021.x ª 2009 John Wiley & Sons A/S. Higher tacrolimus trough levels on days 2 5 post-renal transplant are associated with reduced rates
More informationImmunosuppressant medicines have allowed patients
48 Clinical Pharmacist February 2010 Vol 2 Patients who tolerate a transplanted organ without the need for pharmacological intervention are few and far between. Several immunosuppressants can be used to
More informationEffect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study
NDT Plus (2010) 3 [Suppl 2]: ii32 ii36 doi: 10.1093/ndtplus/sfq064 Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study Miguel Gonzalez-Molina 1, Miguel Angel
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More information